Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation
about
Gene transfer of human TCR in primary murine T cells is improved by pseudo-typing with amphotropic and ecotropic envelopes.CAR-modified T-cell therapy for cancer: an updated review.Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4.Chimeric antigen receptors for T cell immunotherapy: current understanding and future directionsStrategies to endow cytotoxic T lymphocytes or natural killer cells with antibody activity against carcinoembryonic antigen.Engineering T cells for cancer therapy.Supernatural T cells: genetic modification of T cells for cancer therapy.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsCostimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy.Adoptive cellular immunotherapy for childhood malignancies.Treatment of lymphoma with adoptively transferred T cells.Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptorsEnhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner.Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function.A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype.Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells.Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice.Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency.Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model.
P2860
Q33283311-B1E61C71-9986-41EB-A5C4-515BF16BC58DQ34044213-70B5077A-DFF6-4012-9EBD-B6CFD14AF80AQ34055865-3F6C0C49-B422-43ED-800F-F4F6070F670BQ34248531-730CCD3C-F82D-4E52-B453-10141F505270Q35959307-9EF0CF68-074A-47DA-AF6B-F71B2DC0B850Q36298319-F7FB1DD8-C40A-4028-9473-0A4F2BFF7F20Q36328805-9148A75B-0C03-476E-88B2-F61B6A7FA8E7Q36470354-0FC9F516-BD4E-458C-80A5-8BC453AF20A8Q36672822-9A010A8B-16D4-4BA6-8B6B-68E5EEE9021DQ37008216-D74C769C-2DEB-42C0-B00A-F2EA1D83366FQ37419728-78A11EE9-C479-4921-B4B4-47697C48DA2FQ37602251-56C4C8FF-090F-4F55-9CC7-1F595DCFD8E2Q37725751-41BD15EB-7F96-4703-9232-9829A1249FDFQ37751873-34827B88-455C-46BF-BFD2-4E4398D98512Q37861192-8DB35BF5-631C-4034-AD3E-9AD3C0B0041DQ38172451-13A2668C-5464-456A-9C33-181A47F37C31Q38227889-3D0E7195-6CA2-4BE7-8D19-C37079D116CEQ38291751-D5560FC4-AFEF-483D-9444-640146CF20FCQ38525024-761D1B4B-3A7A-4B75-BA86-F4E43E5DFD4BQ39068511-4205DD24-1FA3-4B91-A39E-8B5F4B72000CQ39280002-92559966-AC3D-430D-B22F-962C14D5B942Q40371919-85997ACD-247E-4674-9F81-2629BDD394E5Q40553796-3F1030FE-452A-4C50-9C5E-B69B3142CE5FQ40570652-234C6BAB-C50B-4BE7-8FE7-9F82F857ED31Q43143675-F779CCFC-8814-4560-97C8-BA0F77DC3F57Q45416113-68CE6ED2-1F8C-4310-B245-839F6C865847Q45858756-AA3F893E-CCB5-42A2-BC74-210E81E759CDQ45862006-B0FE8CF4-1470-4D2C-ADF9-F771E5CCAB30Q45876227-12DA8216-1D66-42BB-8AEA-C3C774BA6B37Q45887249-855FC723-95EF-4308-BFA4-2CF869508A1BQ51809142-AFED74AE-7630-42CE-B61C-F8575710B7E3Q54667188-F4B99187-EEA7-4698-91DC-1B74D45480FE
P2860
Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation
description
im November 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 November 2002
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2002
@uk
name
Rejection of Syngeneic Colon C ...... odelivering CD28 Costimulation
@en
Rejection of Syngeneic Colon C ...... odelivering CD28 Costimulation
@nl
type
label
Rejection of Syngeneic Colon C ...... odelivering CD28 Costimulation
@en
Rejection of Syngeneic Colon C ...... odelivering CD28 Costimulation
@nl
prefLabel
Rejection of Syngeneic Colon C ...... odelivering CD28 Costimulation
@en
Rejection of Syngeneic Colon C ...... odelivering CD28 Costimulation
@nl
P2093
P1476
Rejection of syngeneic colon c ...... odelivering CD28 costimulation
@en
P2093
Jacob T Jackson
Loretta Cerruti
Mark J Smyth
Michele W L Teng
Nicole M Haynes
Phillip K Darcy
Stephen M Jane
P304
P356
10.4049/JIMMUNOL.169.10.5780
P407
P577
2002-11-01T00:00:00Z